NEUROCRINE BIOSCIENCES INC

NBIX 10-K · FY 2025
API behind this page

NBIX FY 2025 request

Playground key active
Request URL /api/financials?ticker=NBIX&year=2025&quarter=4&full_year_mode=true
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric FY 2025 FY 2024 YoY
Revenue 2,860.5 2,355.3 +21.4%
Show Product Lines breakouts
Collaboration revenues 26.6 24.7 +7.7%
Product 2,833.9 2,330.6 +21.6%
Show Business Segments breakouts
Reportable Segment 2,860.5 2,355.3 +21.4%
Reportable Segment · CRENESSITY net product sales 301.2 1.7 +17617.6%
Reportable Segment · INGREZZA net product sales 2,513.7 2,313.5 +8.7%
Reportable Segment · Other Income 45.6 40.1 +13.7%
Show Research And Development Arrangement Contract To Perform For Others By Type breakouts
CRENESSITY net product sales 301.2 — —
INGREZZA net product sales 2.51 2.31 +8.7%
Cost of Revenue 52.1 34 +53.2%
Show Business Segments breakouts
Reportable Segment 52.1 34 +53.2%
Research And Development Expense Excluding Acquired In Process Cost 1,015.7 731.1 +38.9%
Show Business Segments breakouts
Reportable Segment 1,015.7 731.1 +38.9%
Reportable Segment · External research and development 507.3 343.5 +47.7%
Reportable Segment · Milestones 65.4 71.7 -8.8%
Reportable Segment · Other research and development 136.6 79.2 +72.5%
Reportable Segment · Payroll and benefits 306.4 236.7 +29.4%
Research And Development Asset Acquired Other Than Through Business Combination Written Off 17.4 12.5 +39.2%
Show Business Segments breakouts
Reportable Segment 17.4 12.5 +39.2%
Selling, General & Administrative 1,156.2 1,007.2 +14.8%
Show Business Segments breakouts
Reportable Segment 1,156.2 1,007.2 +14.8%
Total Costs & Expenses 2,241.4 1,784.8 +25.6%
Operating Income 619.1 570.5 +8.5%
Equity Securities Fv Ni Unrealized Gain Loss -4 -37.1 +89.2%
Show Business Segments breakouts
Reportable Segment -4 -37.1 +89.2%
Investment Income And Other Net 90.3 91 -0.8%
Show Business Segments breakouts
Reportable Segment 90.3 91 -0.8%
Non-Operating Income (Expense) 86.3 -84.5 +202.1%
Income Before Taxes 705.4 486 +45.1%
Income Tax Expense (Benefit) 226.8 144.7 +56.7%
Show Business Segments breakouts
Reportable Segment 226.8 144.7 +56.7%
Net Income 478.6 341.3 +40.2%
Show Business Segments breakouts
Reportable Segment 478.6 341.3 +40.2%
Show Equity Components breakouts
Retained Earnings 478.6 341.3 +40.2%
Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent 3.8 -1.1 +445.5%
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax 3.5 -0.1 +3600.0%
Comprehensive Income 485.9 340.1 +42.9%
EPS (Basic) 4.81 3.4 +41.5%
EPS (Diluted) 4.67 3.29 +41.9%
Wtd Avg Shares (Basic) 99.5 100.4 -0.9%
Wtd Avg Shares (Diluted) 102.5 103.7 -1.2%
Research & Development (FY) — — —
Show Counterparty Name breakouts
2023 Voyager Agreement · Collaborative Arrangement 3 6 -50.0%
Nxera Pharma UK Limited · Collaborative Arrangement 15 50 -70.0%
Takeda · Collaborative Arrangement 37.5 7.5 +400.0%
Xenon · Collaborative Arrangement 7.5 — —
Net Income Loss Available To Common Stockholders Basic 478.6 341.3 +40.2%

Balance Sheet

Balance Sheet
Metric FY 2025 FY 2024 YoY
Current Assets
Cash & Cash Equivalents 713 233 +206.0%
Available For Sale Securities Debt Securities Current 767.4 843.1 -9.0%
Accounts Receivable 686.8 479.1 +43.4%
Inventory 69 57.4 +20.2%
Prepaid Expense Current 170.7 48.5 +252.0%
Other Assets Current 115.8 63.6 +82.1%
Total Current Assets 2,522.7 1,724.7 +46.3%
Non-Current Assets
Deferred Tax Assets 320.3 485.7 -34.1%
Available For Sale Securities Debt Securities Noncurrent 1,063 739.5 +43.7%
Operating Lease Right-of-Use Assets 455.4 509.4 -10.6%
Equity Securities Fv Ni Current And Noncurrent 120.8 124.8 -3.2%
Property, Plant & Equipment 89.8 82.6 +8.7%
Other Non-Current Assets 59.5 52 +14.4%
Total Assets 4,631.5 3,718.7 +24.5%
Current Liabilities
Accounts Payable And Accrued Liabilities Current 674.3 461.6 +46.1%
Other Liabilities Current 69.1 46.1 +49.9%
Total Current Liabilities 743.4 507.7 +46.4%
Non-Current Liabilities
Operating Lease Liabilities 415.3 455.1 -8.7%
Other Non-Current Liabilities 219.7 166.2 +32.2%
Total Liabilities 1,378.4 1,129 +22.1%
Accrued Income Taxes Noncurrent 214.5 160.7 +33.5%
Stockholders' Equity
Common Stock 0.1 0.1 0.0%
Additional Paid In Capital Common Stock 2,792.2 2,554.6 +9.3%
Accumulated Other Comprehensive Income 13.1 5.8 +125.9%
Retained Earnings 447.7 29.2 +1433.2%
Total Stockholders' Equity 3,253.1 2,589.7 +25.6%
Show Equity Components breakouts
Accumulated Other Comprehensive Income 13.1 5.8 +125.9%
Additional Paid In Capital 2,792.2 2,554.6 +9.3%
Common Stock 0.1 0.1 0.0%
Retained Earnings 447.7 29.2 +1433.2%
Total Liabilities & Equity 4,631.5 3,718.7 +24.5%

Cash Flow Statement

Cash Flow Statement
Metric FY 2025 FY 2024 YoY
Operating Activities
Stock-Based Compensation 217.9 195.5 +11.5%
Operating Lease Impairment Loss 0.7 14 -95.0%
Depreciation 26 23.5 +10.6%
Accretion Amortization Of Discounts And Premiums Investments -12.7 -26.2 +51.5%
Amortization Of Intangible Assets 4.1 3.6 +13.9%
Deferred Income Taxes And Tax Credits 165.4 -123.1 +234.4%
Operating Lease Right Of Use Asset Periodic Reduction Net 26.8 10.4 +157.7%
Other Operating Activities Cash Flow Statement 0.7 0.1 +600.0%
Change in Accounts Receivable -210.5 -39.8 -428.9%
Change in Inventory -15.3 -19.1 +19.9%
Increase Decrease In Accounts Payable And Accrued Liabilities 160.2 43.4 +269.1%
Increase Decrease In Income Taxes -18.8 50.3 -137.4%
Increase Decrease In Other Operating Capital Net -44.4 -54 +17.8%
Net Cash from Operations 782.7 595.4 +31.5%
Deferred Income Taxes 164.2 -123 +233.5%
Investing Activities
Purchases of Investments -1,319.8 -1,056.1 -25.0%
Proceeds From Sale And Maturity Of Available For Sale Securities 1,089.4 967.5 +12.6%
Capital Expenditures -34 -38.2 +11.0%
Net Cash from Investing -264.4 -126.8 -108.5%
Financing Activities
Proceeds From Issuance Of Common Stock 129.4 122.1 +6.0%
Share Repurchases -167.7 -300 +44.1%
Show Share Repurchase Program breakouts
Open Market Repurchases -167.7 — —
Net Cash from Financing -38.3 -486.7 +92.1%
Supplemental
Unpaid Capital Expenditures 2.2 2.2 0.0%
Income Taxes Paid 81.4 217.5 -62.6%
Income Taxes Paid 81.4 — —
Other Cash Flow
Net Change in Cash 480 -18.1 +2751.9%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 721 241 +199.2%

Values in millions USD. Source: SEC EDGAR 10-K filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key